Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients with lower urinary tract symptoms by categories of cumulative defined daily doses of therapeutic bladder anticholinergics

From: Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study

 Total
(n = 16,412)
< 28 cDDDs
(n = 13,681)
28–84 cDDDs
(n = 1285)
85–336 cDDDs
(n = 1024)
≥337 cDDDs
(n = 422)
P
n(%)n(%)n(%)n(%)n(%) 
Baseline characteristics
 Age (years), mean (SD)66.5(9.6)66.4(9.8)67.1(8.8)67.2(8.5)67.9(8.1)< 0.001
  50–594346(26.5)3787(27.7)277(21.6)206(20.1)76(18.0)< 0.001
  60–695421(33.0)4441(32.4)447(34.8)377(36.8)156(37.0) 
  70–795192(31.6)4173(30.5)482(37.5)377(36.8)160(37.9) 
   ≥ 801453(8.9)1280(9.4)79(6.1)64(6.3)30(7.1) 
Sex          < 0.001
 Male13,745(83.7)11,312(82.7)1130(87.9)919(89.7)384(91.0) 
 Female2667(16.3)2369(17.3)155(12.1)105(10.3)38(9.0) 
Catastrophic illness certificate2496(15.2)2094(15.3)181(14.1)142(13.9)79(18.7)0.078
Comorbidities
 Diabetes mellitus1093(6.7)950(6.9)56(4.5)57(5.6)30(7.1)0.002
 Hyperlipidemia236(1.4)199(1.5)16(1.3)15(1.5)6(1.4)0.946
 Hypertension2019(12.3)1706(12.5)128(10.0)134(13.1)51(12.1)0.058
 CAD391(2.4)323(2.4)32(2.5)23(2.3)13(3.1)0.787
 CVD452(2.8)392(2.9)27(2.1)23(2.3)10(2.4)0.273
 Atrial fibrillation44(0.3)37(0.3)2(0.2)4(0.4)1(0.2)0.753
 Depression40(0.2)33(0.2)0(0.0)5(0.5)2(0.5)0.087
 TBI20(0.1)19(0.1)1(0.1)0(0.0)0(0.0)0.254
Follow-up characteristics
 Number of outpatient visits per year, mean (SD)27.4(19.9)27.1(19.8)28.0(20.2)28.6(19.5)29.8(20.2)0.003
 Dementia1666(10.2)1372(10.0)115(8.9)118(11.5)61(14.4)0.005
  1. CAD Coronary artery disease, cDDDs Cumulative defined daily doses, CVD Cerebrovascular disease, LUTS Lower urinary tract symptoms, SD Standard deviation, TBI Traumatic brain injury.